Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech

As reported by FierceBiotech

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a prec…

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on FierceBiotech ↗

Market Samachar is a news aggregator. This article was originally published by FierceBiotech. Tap the button above to read the full story on their site.

INDIAN Prediction platform Kalshi targets US oil market with perpetual WTI contract Markets-Economic Times
INDIAN Berkshire Hathaway CEO Greg Abel sees AI, power demand as new engines of growth Markets-Economic Times
INDIAN JM Financial Asset Management garners Rs 700 crore from maiden pre-IPO fund Markets-Economic Times
INDIAN Banks rush to swap higher-risk credit assets for Bank of England cash Markets-Economic Times
COMPANIES Market Trading Guide: Ageis Vopak Terminals among 2 stock recommendations for Thursday Stocks-Markets-Economic Times
INDIAN Dell shares jump 11% after strong AI server demand boosts annual forecast Markets-Economic Times
COMPANIES Rising global bond yields, FCNR-B inflows and SEBI's CAS to shape market dynamics: HDFC Securities CEO Dhiraj Relli Stocks-Markets-Economic Times
INDIAN Jack Daniel's maker misses sales estimates on weak consumer spending Markets-Economic Times

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech

More from Market Samachar